



Journal of Clinical and Experimental Hematopathology (JCEH)

Published on behalf of the Japanese Society for Lymphoreticular Tissue Research and the Japanese Dendritic Cell Society

Online ISSN: 1880-9952

PRODUCT INFORMATION

Aims and Scope

The *Journal of Clinical and Experimental Hematopathology (JCEH)* (the official journal of the Japanese Society for Lymphoreticular Tissue Research and Japanese Dendritic Cell Society) publishes articles describing laboratory and clinical investigations in hematology and related field. The JCEH invites submissions under a broad scope of topics relevant to clinical and experimental hematology research and will consider manuscripts covering all aspects of hematopoiesis, red cells, lymphocytes, phagocytes, dendritic cells, immunobiology and pathophysiology of the hematology system, hematological malignancies, and transplantation. Manuscript categories include **Original Articles, Case report, Short Communications, and Letters to the Editor** written in English. Original Articles will be accepted for publication with the understanding that they have not been published or submitted elsewhere, and Reviews and Commentaries solicited by the Editor-in-Chief may also be published. For any investigation involving human subjects, informed consent must be obtained from the subject(s) and/or their guardian(s), and this must be clearly stated in the manuscript. Animal experiments should be performed according to the relevant guidelines for the care and use of laboratory animals.

Peer review processes

Submitted manuscripts will be sent to peer reviewers. They will generally be reviewed by two experts with the aim of reaching a first decision as soon as possible. Statistical reviewers may be also used where required. Reviewers must declare any competing interests. Reviewers are asked whether the manuscript is scientifically sound and coherent, how interesting it is and whether the quality of the writing is acceptable. Where possible, the final decision is made on the basis that the peer reviewers are in accordance with one another, or that at least there is no dissenting view. In cases where there is disagreement either among peer reviewers or between the authors and peer reviewers, advice is sought from a member of the journal's Editorial Board. The journal allows a maximum of three revisions of any manuscript. The ultimate responsibility for editorial decisions lies with the Editor-in-Chief.

Readership

Hematologists / dermatologists / pathologists / histologists / epidemiologists / virologists / immunologists / oncologists / occupational and environmental health scientists

Keywords

Biology and Immunology of Hematolymphoid Tissues / Reactive, Infectious, and Lymphoproliferative Disorders / Laboratory Methodologies and Technologies / Lymphomas and Lymphoid Leukemias / Myeloma / Plasmacytoma / Lymphoproliferative Disorders (Other Than Overt Neoplasms) / Myeloid Leukemia, Myelodysplastic Syndrome, and Myeloproliferative Disorders / Histiocytic and Dendritic Cell Neoplasms / Non-hematolymphoid Neoplasms

Indexed/Abstracted in: PubMed (NLM), Google

EDITORIAL POLICY

Editor-in-Chief: Professor Naoya Nakamura, Department of pathology, Tokai university school of medicine, 143 Shimokasuya, Isehara-shi, 259-1193, Japan.

The Editor will review all material submitted for publication. Manuscripts that are considered to be of insufficient priority for publication will receive a prompt decision without further review. All other manuscripts are sent to two Editorial Board Members for peer review, and other expert consultants as needed. Peer reviewer identities are kept confidential. Author identities are not kept confidential. All accepted manuscripts become the permanent property and may not be published elsewhere without written permission from the author(s) and the Academy.



Journal of Clinical and Experimental Hematopathology (JCEH)

Published on behalf of the Japanese Society for Lymphoreticular Tissue Research and the Japanese Dendritic Cell Society

Online ISSN: 1880-9952

INSTRUCTIONS FOR AUTHORS

To read about how to prepare your article, please visit on Instruction to Authors. If you are ready to submit an article please click on Online Submission. Additional information and news can be found at Journal homepage (http://www.jsltr.org/eng/journal_list.html).

Instruction to Authors

The Journal of Clinical and Experimental Hematopathology (*JCEH*) invites submission of manuscripts under a broad scope of topics relevant to clinical and experimental hematology research and publishes **Original Articles, Review Articles, Commentaries, Case report Studies, Short Communications, and Letters to the Editor** written in English.

TYPES OF ARTICLES

Original Articles

Full research manuscripts should be as concise as possible, without sacrificing documentation of results. For studies on humans, a clear statement must be provided concerning informed consent, and that the study was conducted after Human Experimentation Review by the relevant committee. Original articles should fit within the categories described below and meet the editorial standards stated.

The journal is pleased to offer a fast publication track for original articles presenting superior novel findings and for studies of greatest priority ranked against similar submissions. The "Fast Track" articles appear earlier than regular manuscripts. Fast Track manuscripts are chosen specifically by the editors according to their judgment and upon the recommendation of reviewers.

Biology and Immunology of Hematolymphoid Tissues
Reactive, Infectious, and Lymphoproliferative Disorders
Laboratory Methodologies and Technologies
Lymphomas and Lymphoid Leukemias
Myeloma/Plasmacytoma
Lymphoproliferative Disorders (Other Than Overt Neoplasms)
Myeloid Leukemia, Myelodysplastic Syndrome, and Myeloproliferative Disorders
Histiocytic and Dendritic Cell Neoplasms
Non-hematolymphoid Neoplasms

Review Articles

Though these are primarily commissioned by the Editors, exceptionally, proposals will be considered and sent for peer review. Presubmission inquiries describing the proposed articles must be sent before submission. The Editors will then indicate whether the review is of potential interest for the journal.

Commentaries

Commentaries present interesting and controversial topics in hematology research, hypotheses, methods and applications. They are meant to promote discussion and generate new ideas for further study.

Case report

Case Studies concerning hematology diseases must provide new information. The journal is also pleased to offer short case study within two printed journal pages.

Short Communications

Articles containing pertinent and interesting observations concerning hematology research in general and reports on new observations or studies that do not warrant publication as a full research article will be considered for the Short Communication section. These articles will undergo full peer review.

Letters to the Editor

Comments on published papers and controversial issues, also including negative data that are of general interest or that contradict commonly accepted concepts or hypotheses, will be considered for publication as Letters to the Editor. In the former case, the Editors may invite letters containing pertinent and interesting observations concerning hematolymphoid research in general, reports on new observations or pilot studies that do not justify a full research article, or comments on published papers will be considered for publication. In the latter case, the Editors may invite the authors of the paper being questioned to respond. Both letters may then be published, if found to be of interest to the Editors.

MANUSCRIPT PREPARATION

Articles should be written in English (American spelling). For any information that is not mentioned in these guidelines, authors should refer to "Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals," as published by the International Committee of Medical Journal Editors (ICMJE).

Original Articles

Original articles should be divided into following sections :

- Title Page with author name(s) and affiliation(s), corresponding author contact information — address, fax, and email —, and a running title (less than 40 letters).
- Non-structured Abstract (maximum 250 words) with three to five unabbreviated keywords · Introduction · Materials and Methods · Results · Discussion · Acknowledgments · References · Tables · Figure Legends · Description of additional data file (if any)

Please note that we cannot process your manuscript if the abstract or the references do not conform to JCEH style.

Short Communications

Short Communications should begin with a title page (with the heading Short Communication and corresponding author contact information — address, fax, and e-mail). Manuscript should not exceed 6,000 words in length.

Letters to the Editor

Letters should begin with a title page (with the heading Letter to the Editor and corresponding author contact information — address, fax, and e-mail). Manuscript should not exceed 4,000 words in length.

General Elements of Manuscripts

Sponsorship and Funding/Financial Disclosure

The Acknowledgments section is an appropriate place to recognize coworkers, indicate funding sources, and disclose information about affiliations and potential conflicts of interest (for example, commercial affiliations, patent-licensing arrangements). Authors must state all their sources of funding and any other financial and personal relationships that might bias their work. If the research reported in the manuscript has received partial or complete funding from commercial sponsors, the authors must also include a statement to that effect. The Editors reserve the right not to consider a manuscript if a sponsor has asserted control over the authors' right to publish their research results. Therefore, if the authors have a potential financial or personal conflict of interest, they must submit the Conflict of Interest form.

Abbreviations

Abbreviations should appear in parentheses immediately after first appearance. Use the abbreviations thereafter in the text.

Unit of Measurement

The following abbreviations should be used : L, mL, dL, m³, kg, g, mg, ng, pg, m, cm, mm, nm, M (molar), mM (millimolar), Gy, °C, min, hr, sec, msec, etc.

Gene Names

Please mark all gene names in italics. Only the gene names should be written in italics, to distinguish them from gene products, gene segments, clusters, families, complexes, or groups. Authors should only use the official gene name as assigned by the respective gene nomenclature committee.

References

References are listed in a separate reference section immediately following the text. All references must be verified by the corresponding author who submits the manuscript to the JCEH. Follow the style of the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" for reference format and Index Medicus for standard journal abbreviations (please see examples below). Number references sequentially in the order cited in the text ; do not alphabetize. A reference cited only in a table or figure is numbered in the sequence established by the first mention in the text of the table or figure containing the reference. Reference to a personal communication or to a manuscript categorized as in preparation or submitted for publication is discouraged. However, if such a reference is essential and refers to a written communication, the source is cited parenthetically in the text (not in the reference section) with the comment "unpublished data" or "personal communication." Written permission

from the source that is cited must be sent to the Editorial Office. Reference to a manuscript accepted but not yet published is listed in the reference section as "in press." "In press" references must be updated by the authors as soon as publication data is available. **Provide names of all authors in a reference when there are five or fewer ; if there are six or more authors, list the first three, followed by "et al."** Journal references shall include the specified information listed in the following order : authors, article title and subtitle, journal abbreviation, volume number in Arabic numerals, inclusive pages :

Tomita S, Kikuti YY, Carreras J, et al. Genomic and immunohistochemical profiles of enteropathy-associated T-cell lymphoma in Japan. Mod Pathol. 2015; 28:1286-1296.

Book references are listed as follows : authors, title, edition (if other than the first), volume (if more than one), city, publisher, pages, and year :

Lennert K, Feller AC: Histopathology of Non-Hodgkin's Lymphomas (Based on the Updated Kiel Classification). 2nd ed, Berlin, Springer-Verlag. 1981; pp. 1- 44.

When referencing a book chapter, the order changes as follows : authors of the chapter, title of the chapter, "In :" editors/authors of the book, title of the book, edition (if there are more than one), volume (if there are more than one), city, publisher, inclusive pages of the chapter, and year :

Stossel TP: The molecular basis of white blood cell motility. In : Stamatoyannopoulos G, Nienhuis AW, Majerus PW, Varmus H (eds) : The Molecular Basis of Blood Diseases. 2nd ed, Philadelphia, Saunders. 1994; pp. 541- 562.

Figures

Authors should upload high-quality graphic data for figures. For use in the peer review process, the Editorial office can use PDF, DOC, PPT, TIF, and JPG files. Figures may be submitted in these formats. However, the preferred format is PPT, TIF, or JPG files, which would be required when the manuscript is accepted.

Electronic Supplementary Material

Material that is not suitable for print publication such as very long tables, database information, etc. can be published online as electronic supplementary material. The final decision to do so, however, lies with the Editors. Please submit camera-ready files for this material as it will not be edited or altered in any way by the publisher.

Clinical Trials

As described in the ICMJE's policy on trial registration, all clinical trials must be registered with a public trials registry before the time of first patient enrollment. ICMJE defines clinical trials as any research project that prospectively assigns people or a group of people to an intervention, with or without concurrent comparison or control groups, to study the cause-and-effect relationship between a health-related intervention and a health outcome. Health-related interventions includes but not limited to those used to modify a biomedical or health-related outcome; examples include drugs, surgical procedures, devices, behavioral treatments, educational programs, dietary interventions, quality improvement interventions, and process-of-care changes.

Authors are required to register all clinical trials with databases managed by a non-profit organization, openly accessible to the public free of charge, have a mechanism to ensure the validity of the registration data, and are electronically searchable. The registration must be made with the registries listed at <http://www.icmje.org>

For more details, please go to the International Committee of Medical Journal Editors (ICMJE) site at <http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html>

Reporting Guidelines

Authors are encouraged to follow published standard reporting guidelines for the study discipline.

CONSORT for randomized clinical trials (<http://www.consort-statement.org/>)

CARE for case reports (<http://care-statement.org/>)

STROBE for observational studies (<http://strobe-statement.org/>)

PRISMA for systematic reviews and meta-analyses (<http://prisma-statement.org/>)

STARD for studies of diagnostic accuracy (<http://www.stard-statement.org/>)

Please access <http://www.equator-network.org/> to find the guideline that is appropriate for your study.

EDITORIAL PROCESS

All manuscripts are assessed initially by the editors. A selection of manuscripts is then sent for review to experts in the field. When a decision is reached, a decision letter is sent to the authors by e-mail with the comments of the referees. Decision letters for manuscripts not sent for review are also sent by email. To aid in the peer review, we invite authors to suggest potential reviewers of their manuscript (including affiliation, address, and e-mail) in the online submission procedure. The authors also have the option of naming non-preferred reviewers. Receipt of a manuscript is acknowledged by e-mail. We remind you that in submitting to JCEH you agree that

your work is original in presentation and content and that the work has neither been published elsewhere — including being posted on any site on the Internet — nor is simultaneously under submission as a complete manuscript with another journal.

ONLINE SUBMISSION

Manuscripts must be submitted by one of the authors of the manuscript, and should not be submitted by anyone on their behalf. The submitting author takes responsibility for the article during submission and peer review. To facilitate rapid publication and to minimize administrative costs, JCEH receives only online submission.

New Submissions

Please submit all new manuscripts online. Individual files should be uploaded for the text (PDF or DOC format), tables (PDF or DOC for text), and figures (PPT, TIF, or JPG). You do not need to mail any copies. Launch your web browser and go to

http://www.jsltr.org/jceh_online.html for Japanese author(s) or

http://www.jsltr.org/eng/jceh_online_en.html for non-Japanese author(s).

Please create a new account on submission. Follow the step-by-step instructions. Please note that the manuscript should be submitted by or on behalf of the corresponding author. At the end of a successful submission, a confirmation screen with a manuscript number will appear and you will receive an e-mail confirming that the manuscript has been received by the journal and you will find out your new Login ID (Manuscript Number or Submission Number) and password. If this does not happen, please check your submission.

To visit your submission again you need go to http://www.jsltr.org/jceh_online.html for Japanese author(s) or http://www.jsltr.org/eng/jceh_online_en.html for non-Japanese author(s), and input with new ID Number and password.

Please contact the Editorial Office by e-mail regarding specific requirements.

Required Documents for New Submissions

For new submissions we require the following documents, which can be uploaded as a PDF or DOC file to the web or sent to us by e-mail. They can be submitted by e-mail, or uploaded to the web site along with the manuscript.

Covering Letter. Please introduce your work in a covering letter with addressing the aim of the study, the significant and novel findings, and the relationship to the present state of the field.

Submission Form. The Journal requires the consent of all authors upon submission, verifying agreement with content and presentation, and knowledge of submission to JCEH. Each author who has conflict of interest must submit the Conflict of Interest form. The manuscript cannot be processed until these forms are complete.

Letter of Permission. Permission is required from the appropriate investigators when "personal communication" or "unpublished data" is cited in the manuscript or from the publisher if previously published material has been used in the manuscript.

Submission of Revised Manuscripts

If you have been invited to submit a revised manuscript, please re-submit it online via

<http://ess.jstage.jst.go.jp/contrib/jslrt/main/-char/ja> for Japanese author(s) or

<http://ess.jstage.jst.go.jp/contrib/jslrt/main/-char/en> for non-Japanese author(s) with new ID

Number and password, which you already received by e-mail after initial submission.

Instructions can be found there : Enter your point-by-point responses to the reviewers separately in the Response File. Upload two versions of the revised manuscript, one clean copy and another with all changes underlined or marked. Please also re-upload figures and tables.

EDITORIAL DECISIONS

Rejected Manuscripts

Manuscripts may be rejected either based on the opinions of the Editors or based on the comments of reviewers. Manuscripts not reaching a high enough level of priority or not fitting within the scope of the Journal will be returned to authors without detailed comments. Only manuscripts of high priority will be considered.

Revisions Requested

If the Editors and the reviewers respond positively to a manuscript and are interested in considering it further after additional work is included, authors will be invited to resubmit the manuscript to JCEH. A decision letter will be sent by e-mail containing the comments of the reviewers. We ask that revisions are made within 3 months. Any questions concerning the requested changes/additional work should be addressed to the Editors by e-mail before submission of the revised manuscript. Revised manuscripts may be returned to the original reviewers for reassessment. Therefore, the review process of the revised manuscript may take over a month in some cases. The Editors maintain the option to reject a manuscript in a second or third round of revision if the specific concerns have not been met or if the manuscript still does not meet a high enough level of priority. Please always include the manuscript number in any correspondence and the submission documents.

Accepted Manuscripts

When a manuscript is accepted for publication by the editors, it is sent to the publisher for typesetting, copy editing and printing. An electronic proof of the typeset and copy edited version will be sent to the author for approval. We ask that you report any changes immediately to the publisher. Manuscripts will be held in the editorial office if outstanding materials are required (accepted version of the manuscript and conflict of interest form if this has not been submitted previously). Electronic proofs may take approximately 8 weeks to generate. The publisher may be contacted with questions about proofs. Authors submitting articles to JCEH agree that, if accepted, the copyright of the article, including the right of reproduction in all forms and media, will belong exclusively to the Japanese Society of Lymphoreticular Tissue Research.

PUBLICATION AND TECHNICAL INFORMATION

Guidelines for Final Version of Accepted Manuscripts

The final versions of accepted manuscripts (text, tables and figures) should be uploaded online. After publication, further changes, or corrections, can only be made in the form of an Erratum which will be hyperlinked to the original article.

Text

Software and Format. Only Microsoft Word (DOC file) is available for the latest version, although manuscripts prepared with other operating systems and software may be accommodated. Do not use desktop publishing software such as Aldus PageMaker or Quark X Press. If you prepared your manuscript with one of these programs, including EndNote, please export the text to a word processing format.

Figures

Authors should upload high-quality graphic data for figures. The required format is PPT, JPG, or TIF. All color figures will be reproduced in full color in the online edition of the journal at no cost to authors. Authors are requested to pay the cost of reproducing color figures in print. When necessary to convey essential scientific information authors are encouraged to submit color illustrations. For best reproduction, bright, clear colors should be used. Dark colors against a dark background do not reproduce well ; please place your color images against a white background wherever possible. All print reproduction requires files for full color images to be in a CMYK color space.

Software and Format. All figures of accepted manuscripts should be in PPT, JPG or TIF format.

Resolution. The minimum requirements for resolution are : 1,200 DPI/ PPI for black and white images, such as line drawings or graphs. 300 DPI/PPI for picture-only photographs 600 DPI/ PPI for photographs containing pictures and line elements, i.e., text labels, thin lines, and arrows. These resolutions refer to the output size of the file ; if you anticipate that your images will be enlarged or reduced, resolutions should be adjusted accordingly.

Color Art. Resolution should be at least 300 DPI for all color figures. Files must be in CMYK format.

File names. Illustration files should be named by the figure number and the 3- letter extension that identifies the file format used (i.e., .ppt, .jpg or.tif).

Charges

Page Charges Publication fee of 30,000 Japanese yen will be charged at the time of acceptance of manuscript for publication in JCEH.

English Language Charges Authors are responsible for the linguistic accuracy of their manuscripts. The cost of English revision by the Language Consultant according to the extent of the revision will be charged to the author.

Offprints Offprint order forms are sent to authors with their proofs, which should be used to order all offprints. The order form must be returned with the proofs. Late orders may be charged at higher rates (orders will not be processed if received after the issue has gone to press). Offprints are supplied at a rate based on the number of pages in the printed article and the number of offprints ordered (refer Offprint Order Form indicated below). There is a minimum order quantity of 50 copies.

Japanese contributors must pay not only a total due of page charges and offprints charges but also a 8%-consumption tax on a total due. Overseas contributors must remit 4,000 yen for a bank handling commission in addition to a total due of page charges, English language charges and offprints charges, and a 8%-consumption tax, by bank draft or a remittance check. The payment by credit card is not available.

EDITORIAL POLICIES

Overview

JCEH supports and adheres to the guidelines and best practices including Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (<http://www.icmje.org/icmje-recommendations.pdf>) by the International Committee of Medical Journals Editors (ICMJE) and the Principles of Transparency and Best Practice in Scholarly

Publishing (a joint statement by the Committee on Publication Ethics (COPE), the Directory of Open Access Journals (DOAJ), the World Association for Medical Editors (WAME) and the Open Access Scholarly Publishers Association (OASPA); (<http://doaj.org/bestpractice>).

Authorship

According to [the ICMJE's Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals](#), all authors listed in the manuscript must meet the following criteria of contribution:

1. Substantial contributions to the conception or design of the research or the acquisition and analysis of data
2. Drafting the work or revising it critically for important intellectual content
3. Final approval of the version to be published
4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Contributors who do not meet the criteria above should not be listed as authors.

Those who do not qualify for an authorship may be acknowledged under a single heading with "Acknowledgements". Examples of activities that do not qualify a contributor for authorship are acquisition of funding, general supervision of a research group, or general administrative support and writing assistance, technical editing, language editing, and proofreading.

Conflict of Interest

JCEH requires authors and editors to disclose any potential conflict of interest related to articles submitted for publication. A conflict of interest exists when anyone has financial or personal relationships that could inappropriately influence (bias) toward his or her actions. The intent of the JSLTR conflict of interest disclosure policy is to provide authors, editors, and readers with all the facts necessary to make informed judgments about the content of JCEH.

All authors are required to complete a conflict of interest form as a part of the manuscript submission process. Further details and the form can be downloaded from the following link http://www.jsltr.org/jp/1308/rieki_style02.pdf

Publication Ethics

1) Manuscripts, which report on human subjects or materials of human origin, must comply with the provisions of the Declaration of Helsinki, and it must be mentioned that the study had been approved by the relevant institutional or national review board (IRB). If approval from any IRB was not required, it must be explicitly stated in the manuscript.

2) For all studies involves human subject must clearly state in the manuscript that written consent has been obtained from all patients (or the parent or the legal guardian of the patient) to publish the information.

3) Any data or information such as patient names, initials, hospital patient identification codes (patient IDs), specific dates, or any other information which may identify patients must not be presented anywhere in the manuscript, including the Figures and Tables.

4) Articles reporting on data from animal testing must comply with institutional, national, or international guidelines must state in the "Materials and Methods" section the approval of the testing design by the affiliated institution's animal care and use committee, if available.

Redundant or Duplicate Publication

Articles that are under review elsewhere or being published in another journal, including advanced publications ("in-press" or "E-pub ahead of print"), in any language might be regarded as redundant or duplicate publication.

Abstracts or posters presented at scientific meetings are not considered previously published work.

In case of violation of redundant or duplicate publication policy, the Editorial Board will take sanctions such as immediate rejection of the submitted manuscript, retraction of published work, and banning of future manuscript submission.

Misconducts and Breach of Publication Ethics

Upon submitting a manuscript to JCEH, authors must agree and guarantee that submitted work is original in presentation and content and that the work has neither been published elsewhere, nor is simultaneously under submission as a complete manuscript with another journal.

All authors are fully responsible for the originality and contents of their submitted work. All records and data presented in the manuscript must be accurate, without any fabrication, manipulation, or falsification.

All information and contents that originate from other resources must be credited and cited, as guided in the "References" section.

Any identified or suspicious misconducts are subject to investigation by the Editorial Board of JCEH according to the guidelines recommended by COPE. If the allegation raises any valid concerns after the investigation, the author will be contacted to address the issue. The Editor-in-Chief may decide to publish an "Expression of Concern" if suspicion is raised after the article has already been published. If misconduct or the breach of publication ethics is established,

regardless of the severity, this may result in a retraction of the paper, publication of formal notice of misconduct, formal notice to an author's institution, and formal embargo on future submission to JCEH.

COPYRIGHT

Copyright of articles and their contents belong exclusively to the Japanese Society of Lymphoreticular Tissue Research.

JCEH is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (<https://creativecommons.org/licenses/by-nc-nd/4.0/>). Anyone may download, reuse, copy, reprint, distribute, or modify articles published in the journal for not-for-profit purposes if they cite the original authors and source properly. If anyone remix, transform, or build upon the material, the user must distribute their contributions under the same license. For for-profit or commercial use, a written permission by the Editorial Committee of JCEH is mandatory.

ADVERTISEMENT

JCEH does not accept advertising from pharmaceutical companies, device manufacturers, or any other commercial entities to avoid potential conflicts of interest in editorial decision-making.

CONTACT INFORMATION

We invite inquiries to the editorial office at any time during the editorial process. For all matters concerning presubmission, editorial policies and procedures, and general production matters, please contact the editorial office described below :

Address for Contact

Professor Naoya nakamura
Editor-In-Chief
Journal of Clinical and Experimental Hematopathology
Department of Pathological Diagnostics
Tokai university school of medicine
143 Shimokasuya, Isehara-shi, 259-1193, Japan
TEL: +81-463-93-1121
FAX: +81-463-91-1371
e-mail : naoya@is.icc.u-tokai.ac.jp

Electric Forms

[Permission Request Form](#)
[Conflict of Interest Form](#)
[Offprint Order Form](#)